Aminocaproic Acid
NDC Package 69315-232-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Aminocaproic Acid is a medication used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). Marketed by Leading Pharma, Llc, this product is identified by NDC 69315-232 and is authorized under FDA application ANDA213928.

Identification & Billing

NDC Package Code
69315-232-03
Package Description
30 TABLET in 1 BOTTLE
Product Code
69315-232
11-Digit Billing Format
69315023203
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA

Clinical Specifications

Proprietary Name
Aminocaproic Acid
Dosage Form
-
Usage Information
This medication is used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). This may cause serious bleeding after certain surgeries or in certain conditions (such as bleeding disorders, liver disease, cancer). Aminocaproic acid works by helping your blood clot normally. It belongs to a class of drugs known as antifibrinolytics.

Regulatory & Marketing

Labeler Name
Leading Pharma, Llc
FDA Application #
ANDA213928
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-15-2021
End Marketing Date
04-21-2023
Listing Expiration
04-21-2023
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69315-232-03 identifies a specific commercial package of 30 tablet in 1 bottle of Aminocaproic Acid, labeled by Leading Pharma, Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Leading Pharma, Llc on March 15, 2021. The current certification is valid through April 21, 2023.

What are the primary indications for this medication?

This medication is used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). This may cause serious bleeding after certain surgeries or in certain conditions (such as bleeding disorders, liver disease, cancer). Aminocaproic acid works by helping your blood clot normally. It belongs to a class of drugs known as antifibrinolytics.

How is this Leading Pharma, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69315023203. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69315-232-03
11-Digit CMS (5-4-2)
69315-0232-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.